One in five pharmacies blocks access to key medication to treat addiction
Research News Release
EurekAlert! provides eligible reporters with free access to embargoed and breaking news releases.
Eligibility GuidelinesEurekAlert! offers eligible public information officers paid access to a reliable news release distribution service.
Eligibility Guidelines
EurekAlert! is a service of the American Association for the Advancement of Science.
One out of five pharmacies refuse to dispense a key medication to treat addiction, according to an audit of hundreds of pharmacies nationwide. Researchers found found that independent pharmacies and those in southern U.S. states were significantly more likely to restrict access to buprenorphine, also known as Suboxone.
Researchers have created to novel biobanks of diverse tissues from animals to further explore the biological bases and consequences of addiction to cocaine and oxycodone.
What The Study Did: This survey study looked at how common is the use of marijuana in e-cigarettes among students in grades 6 to 12 and also changes in use by racial and ethnic groups from 2017 to 2020.
What The Study Did: Researchers investigated racial/ethnic representation in clinical trials that led to U.S. Food and Drug Administration approval of ophthalmology drugs from 2000 to 2020.
What The Study Did: Claims data were used to look at opioid use among young people (ages 10 to 21) who had been prescribed opioids for the first time.
Babies born to mothers diagnosed with cannabis use disorder are more likely to experience negative health outcomes, such as preterm birth and low birth weight, than babies born to mothers without a cannabis use disorder diagnosis, report UC San Diego researchers.
A new study of nearly five million live births recorded in California from 2001 to 2012 found that babies born to mothers diagnosed with cannabis use disorders at delivery were more likely to experience negative health outcomes, including preterm birth and low birth weight, compared to babies born to mothers without a cannabis use disorder diagnosis.
People who regularly use psychoactive substances report experiencing a variety of negative impacts since the COVID-19 pandemic began, including increased usage and fear of relapse or overdose, highlighting the need for improved supports and services, including better access to safe supply programs, according to a new CAMH survey published in the International Journal of Drug Policy.
A study published this week in The Lancet Public Health examines how we can use our income assistance systems to address drug use and drug-related harm.
What The Study Did: Data from the Ohio Department of Health were used to evaluate changes in drug overdose mortality in that state by type of drug and age of the user during the first seven months of the COVID-19 epidemic.